Paper · 42860404

Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.

Wu K and 9 others. Signal Transduct Target Ther, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics. Papers, record 42860404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42860404

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.
Journal: Signal Transduct Target Ther
Year: 2026
Publication types: Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed: https://pubmed.ncbi.nlm.nih.gov/42860404/
DOI: https://doi.org/10.1038/s41392-026-02840-z
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13654986/
The journal: https://conductscience.org/library/journal-index/101676423
Revised in PubMed: 2026-10-18

Source PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Wu K	Kai
2	Ji J	Jia
3	Sun T	Ting
4	Lv D	Dan
5	Pan J	Jingying
6	Wei M	Mudan
7	Zhu M	Miaojin
8	Wang M	Minghai
9	Li L	Lanjuan
10	Yao H	Hangping	https://orcid.org/0000-0001-6742-7074

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Receptor Protein-Tyrosine Kinases	Major topic
Neoplasms	Major topic
Molecular Targeted Therapy	Major topic
Protein Kinase Inhibitors	Major topic
Humans
Signal Transduction
Tumor Microenvironment
Animals

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
82473937	National Natural Science Foundation of China (National Science Foundation of China)			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References492

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	30,808,022	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.	Brain	2019	https://conductscience.org/library/papers/30808022	PubMed
2	29,535,161	IGF1 receptor signaling pathways.	J Mol Endocrinol	2018	https://conductscience.org/library/papers/29535161	PubMed
3	17,449,137	RNAi therapeutics: principles, prospects and challenges.	Adv Drug Deliv Rev	2007	https://conductscience.org/library/papers/17449137	PubMed
4	20,380,722	Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes.	Arthritis Res Ther	2010	https://conductscience.org/library/papers/20380722	PubMed
5	35,063,535	RNAi-based therapeutics and tumor targeted delivery in cancer.	Adv Drug Deliv Rev	2022	https://conductscience.org/library/papers/35063535	PubMed
6	22,827,778	The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer.	J Biomed Sci	2012	https://conductscience.org/library/papers/22827778	PubMed
7	31,825,192	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.	N Engl J Med	2020	https://conductscience.org/library/papers/31825192	PubMed
8	40,610,005	G Protein-coupled and Membrane Tyrosine Kinase Receptor Relationships Yield Therapeutic Opportunities.	Endocr Rev	2025	https://conductscience.org/library/papers/40610005	PubMed
9	22,081,023	A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism.	Nat Med	2011	https://conductscience.org/library/papers/22081023	PubMed
10	35,363,627	Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial.	Clin Transl Gastroenterol	2022	https://conductscience.org/library/papers/35363627	PubMed

1 to 10 of 492

See all 492 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42860404

GET https://conductscience.org/api/papers/v1/42860404/references?page=2

API reference For AI assistants